# Tirzepatide Cuts BMI in Adolescents With Obesity in Phase III Trial

Source: [MedPageToday.com - medical news for physicians](https://www.medpagetoday.com/meetingcoverage/obesityweek/123891) · 2026-11-15 · Medicine
Page: https://themorning.science/story/tirzepatide-cuts-bmi-in-adolescents-with-obesity-in-phase-iii-trial-5e934acfd4931941
Kind: research · Impact: medium

## In brief

- Tirzepatide (Zepbound) produced substantial reductions in BMI among adolescents with obesity or overweight with obesity-related complications.
- The results come from the phase III SURMOUNT-ADOLESCENTS trial.
- The findings were reported at ObesityWeek in National Harbor, Md.

## Why it matters

The phase III trial provides evidence on BMI outcomes of tirzepatide in adolescents, a population with fewer treatment studies than adults.

## Timeline

- 2026-11-16: Phase III SURMOUNT-ADOLESCENTS results presented at ObesityWeek

## Coverage

- [Tirzepatide Cuts BMI in Adolescents With Obesity in Phase III Trial](https://www.medpagetoday.com/meetingcoverage/obesityweek/123891) — MedPageToday.com - medical news for physicians, 2026-11-15

Tags: tirzepatide, obesity, adolescents, clinical trial, bmi, weight management

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
